- Home
- LRMR vs RGNX Comparison
LRMR vs RGNX Comparison
Compare LRMR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- RGNX
- Stock Information
- Founded
- LRMR N/A
- RGNX 2008
- Country
- LRMR United States
- RGNX United States
- Employees
- LRMR N/A
- RGNX N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LRMR Health Care
- RGNX Health Care
- Exchange
- LRMR Nasdaq
- RGNX Nasdaq
- Market Cap
- LRMR 426.9M
- RGNX 372.1M
- IPO Year
- LRMR N/A
- RGNX 2015
- Fundamental
- Price
- LRMR $3.34
- RGNX $7.37
- Analyst Decision
- LRMR Strong Buy
- RGNX Strong Buy
- Analyst Count
- LRMR 8
- RGNX 12
- Target Price
- LRMR $19.63
- RGNX $36.00
- AVG Volume (30 Days)
- LRMR 678.8K
- RGNX 1.8M
- Earning Date
- LRMR 03-13-2025
- RGNX 02-25-2025
- Dividend Yield
- LRMR N/A
- RGNX N/A
- EPS Growth
- LRMR N/A
- RGNX N/A
- EPS
- LRMR N/A
- RGNX N/A
- Revenue
- LRMR N/A
- RGNX $84,327,000.00
- Revenue This Year
- LRMR N/A
- RGNX $2.92
- Revenue Next Year
- LRMR N/A
- RGNX $234.86
- P/E Ratio
- LRMR N/A
- RGNX N/A
- Revenue Growth
- LRMR N/A
- RGNX N/A
- 52 Week Low
- LRMR $3.01
- RGNX $6.56
- 52 Week High
- LRMR $13.68
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- LRMR 29.00
- RGNX 42.98
- Support Level
- LRMR $3.24
- RGNX $6.98
- Resistance Level
- LRMR $3.54
- RGNX $7.70
- Average True Range (ATR)
- LRMR 0.22
- RGNX 0.57
- MACD
- LRMR 0.03
- RGNX 0.02
- Stochastic Oscillator
- LRMR 12.26
- RGNX 35.53
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.